A North Carolina-based drugmaker recently tightened its 340B contract pharmacy restrictions to limit distribution of a pulmonary arterial hypertension treatment—just [...] …
Blog Posts
SPONSORED CONTENT
Since this article was published, HRSA released new guidance on a proposed pilot rebate model. This pilot would permit manufacturers to offer 340B rebates for a limited set of drugs under defined conditions. Read more in 340B
…
AbbVie and Novartis recently became the first drugmakers to file lawsuits challenging Oregon’s new law prohibiting 340B contract pharmacy restrictions. [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
340B covered entities and drugmakers offered competing criticisms Thursday of the Health Resources and Services Administration’s (HRSA) newly released 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The Health Resources and Services Administration (HRSA) today unveiled its highly anticipated 340B rebate guidance, proposing a pilot program that [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Three federal appeals judges—who have all ruled on 340B matters in the past—will hear oral arguments in September in a [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A majority of 340B hospitals surveyed said the costs associated with implementing drugmakers’ proposed rebate models would hinder their ability [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The dark money group behind a campaign targeting GOP-led states’ recent efforts to enact 340B contract pharmacy access laws released [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
The regulatory landscape for the 340B drug pricing program is evolving rapidly. As scrutiny from the Health Resources and Services Administration (HRSA) and drug manufacturers intensifies, healthcare leaders and 340B teams face growing pressure to maintain airtight
…